EQRx

Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSCLC

Shots: The companies collaborated to assess Turning Point’s elzovantinib (TPX-0022) in combination with EQRx’s aumolertinib in patients with EGFR mutant MET-amplified advanced NSCLC Turning Point will sponsor and conduct a P-Ib/II clinical trial to evaluate the safety, tolerability and preliminary efficacy of the combination regimen and will assume all costs associated with the trial whereas …

Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSCLC Read More »

CStone Signs an Out-Licensing Agreement with EQRx for Sugemalimab and CS1003

Shots: CStone to receive $150M up front and $1.15B as milestones for both drugs along with royalties on each drug. EQRx get an exclusive right to lead global development and commercialization excluding Mainland China, Taiwan, Hong Kong, and Macau CStone retains rights to CS1003 in Greater China, where it will pursue development as a monothx. …

CStone Signs an Out-Licensing Agreement with EQRx for Sugemalimab and CS1003 Read More »